COVID-19: combining antiviral and anti-inflammatory treatments

Justin Stebbing; Anne M. Phelan; Ivan Griffin; Catherine Tucker; Olly Oechsle; D. Casey Smith; Peter J. Richardson

doi:10.1016/s1473-3099(20)30132-8

Keywords

MedicineScopusCoronavirus disease 2019 (COVID-19)CoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyMEDLINEInternal medicineDiseaseBiologyInfectious disease (medical specialty)

Affiliated Institutions

Related Publications

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Yadi Zhou , Yuan Hou , Jiayu Shen +3 more

Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epi...

2020 Cell Discovery 1664 citations

Characteristics of SARS-CoV-2 and COVID-19

Ben Hu , Hua Guo , Peng Zhou +1 more

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute re...

2020 Nature Reviews Microbiology 5269 citations

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

Hongzhou Lu

As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no ...

2020 BioScience Trends 1183 citations

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Meijuan Zheng , Yong Gao , Gang Wang +5 more

In December 2019, a novel coronavirus was first reported in Wuhan, China. It was named by the World Health Organization as severe acute respiratory syndrome coronavirus 2 (SARS-...

2020 Cellular and Molecular Immunology 1841 citations

SARS-CoV-2 vaccines in development

Florian Krammer

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pande...

2020 Nature 2193 citations

Publication Info

Year: 2020
Type: letter
Volume: 20
Issue: 4
Pages: 400-402
Citations: 1143
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

COVID-19: combining antiviral and anti-inflammatory treatments

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1143

OpenAlex

Cite This

APA Style

                            
                                
                                    Justin Stebbing, 
                                
                                    Anne M. Phelan, 
                                
                                    Ivan Griffin
                                
                                et al.
                            
                            (2020). 
                            COVID-19: combining antiviral and anti-inflammatory treatments. 
                            The Lancet Infectious Diseases
                            , 20
                            (4)
                            , 400-402.
                            https://doi.org/10.1016/s1473-3099(20)30132-8
                        

Identifiers

DOI: 10.1016/s1473-3099(20)30132-8